Files

Download

Download Full Text (432 KB)

Description

Nationwide prevalence of obesity is related to comorbidities including heart disease, type 2 diabetes, and stroke. The United States spends nearly $173 billion annually for the medical cost of obesity, and obese adults have a difference of $1,861 of medical costs than those with healthy weight (CDC, 2022). Overweight individuals experience chronic health issues, resuling in a significant financial burden due to increased costs associated with medical treatment. Ozempic is a newly approved drug accepted by the FDA in 2017 to treat diabetes but is now gradually being implemented as a weight loss medication. It is used in conjunction with exercise and diet in adults with type 2 diabetes mellitus to improve glycemic control; however, continuous nutrition treatment is necessary in order to prevent rebound weight gain. Obesity is a significant public health challenge in the United States resulting from lack of access to education and networks to health and nutrition. Ethnicity and a community’s socio-economic factors play a role in proper access to education of healthy management of weight loss. Further problems arise when young adults discontinue weight loss medication without the proper support of nutrition education and an exercise regime. In order to sustain clinical weight loss and decrease the susceptibility of comorbid risks, lifestyle interventions are advised (Amaro, 2022). There is limited research on interventions to help with preventing weight gain after discontinuing medication.

Department

Nursing

Publication Date

2024

Sponsorship/Conference/Institution

Scholar & Creative Works Conference, Dominican University of California

City

San Rafael, CA

Keywords

adolescents, school-based interventions, health conditions, diet, weight loss

Disciplines

Education | Food Studies | Nursing | Social and Behavioral Sciences

Incorporation of Nutrition Education with Medication Inject to sustain Weight Loss


Share

COinS